As compounding pharmacists, we’re often on the front lines when patients and providers start exploring emerging therapies — especially those that live in the grey space between hopeful promise and clinical validation. The recent PCCA webinar on Mebendazole and Ivermectin in Oncology addressed just that. If you missed it, here are the key takeaways, insights and cautionary notes from the session — tailored for your role behind the counter and in the consult room.

At PCCA, we strive to lead through innovation and are defined by our unwavering commitment to quality. That’s why we’re proud to share some exciting news: LoxOral® and Anhydrous SuspendIt®, two of our most widely used proprietary bases, are now part of the U.S. Pharmacopeia (USP) Ingredient Verification Program for Excipients.

In a culture that often celebrates hustle and productivity, sleep tends to fall low on the priority list. Yet, getting enough high-quality sleep is one of the most powerful tools for maintaining long-term health. It's not just about avoiding grogginess the next day — sleep plays a key role in everything from physical repair to emotional resilience and mental sharpness.

In the world of GLP-1 receptor agonists, semaglutide has become a key player for several health conditions. But with growing patient demand and evolving regulations, healthcare providers are looking beyond traditional injections to explore new ways to deliver this powerful therapy.

Running a pharmacy without a strategy is like navigating a stormy sea without a compass. As a pharmacy owner, you're often caught up in daily operations, reacting to the chaos of the days, weeks and months. Before you know it, the year has flown by and you're simply celebrating survival. This article explains how strategic planning benefits your practice, including tips to get started.

Bacterial vaginosis (BV) is the most common vaginal infection that affects women around the globe. In addition to its effects on total health, BV can significantly impact reproductive wellness. The condition is thought to originate from a decrease of Lactobacilli in the vagina, resulting in an imbalance in the natural vaginal microbiome.1 In the following article, we explore the pathogens associated with BV and challenges with commercial treatments, as well as compounding options and an innovative base that may potentially improve patient compliance.

The fundamental purpose of hospice is to help patients retain comfort, dignity and quality of life as they approach the end of life. During this stage, nausea and vomiting — either caused by medication side effects or from symptoms of a disease — are common. These and other side effects may lead to unnecessary stress and patient discomfort. In the following article, we review a commonly used topical gel that lessens nausea and vomiting, as well as the PCCA base vehicle that may enhance penetration of active pharmaceutical ingredients (APIs).

USP 800 discusses Environmental Quality and Control (Section 6) related to environmental wipe sampling for hazardous drug (HD) surface residue. This is not a requirement in USP 800; instead, it is stated that this should be performed routinely. What does this mean for those who handle HDs and why should compounders consider performing routine HD wipe sampling?

Sections of the FDA’s Drug Quality and Security Act (DQSA) distinguish compounding pharmacies (503A) from outsourcing facilities (503B). Due to several factors, many of which are related to drug shortages and the USP 797/USP 800 updates, 503A pharmacies are considering partnering with 503B entities for compounded sterile preparations and/or hazardous materials. We’ll discuss the differences between 503A pharmacies and 503B outsourcing facilities, review Section 503B and summarize how to effectively evaluate 503B compounding pharmacies for a potential partnership.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized metabolic health and weight management, leading to a host of new weight loss wonder drugs. But did you know that recent evidence shows these new drugs may do more than just help with weight loss and diabetes? And at a fraction of the standard dose?